乘聯會料8月內地新能源乘用車廠商批發銷量80萬輛 按年增長27%
乘聯會公布,今年內地新能源乘用車發展優勢不斷鞏固和擴大,綜合預估8月乘聯會新能源乘用車廠商批發銷量80萬輛,按年增長27%,按月增長9%。今年以來累計批發508萬輛,按年增長39%。
當中,預期8月份比亞迪(01211.HK)批發銷量27.41萬輛;特斯拉中國料8.42萬輛;廣汽埃安料5.21萬輛;吉利(00175.HK)料4.73萬輛。
乘聯會預測,2023年中國新能源乘用車銷量為850萬輛,狹義乘用車銷量為2,350萬輛,年度新能源車滲透率有望達到36%。目前運行狀態與預測基本吻合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.